Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders
Editor in chief: Jun WANG
Chinese Journal of Alzheimer's Disease and Related Disorders >
Application of PDCA cycle management on the rational use of benzodiazepines in dementia patients with sleep disorders
Received date: 2020-11-15
Revised date: 2020-12-20
Online published: 2021-03-25
To evaluate the effect of PDCA cycle management to improve the rational use of benzodiazepines for dementia patients with sleep disorders.
In November 2018, the quality assessment group was set up and analyzed the situation of benzodiazepines for dementia patients with sleep disorders during the last four months. The use of benzodiazepines was managed using PDCA cycle from December 2018 to January 2020. The rate of assessment in sleep, rational use of benzodiazepines and incidence rate of adverse effects were compared before and after implementation of PDCA cycle.
After 4 to 7 PDCA cycles, the evaluation rate of sleep disorders in patients with dementia increased from 7.1% to 98.0%(P < 0.01), and the rational use of benzodiazepines in dementia with sleep disorders increased from 44.7% to 99.0%(P < 0.01). The total adverse effects rate dropped significantly(P < 0.05).
The PDCA cycle can effectively promote the rational use of benzodiazepines in dementia with sleep disorders, which is worth popularizing in clinical practice.
Key words: PDCA cycle; dementia; sleep disorder; benzodiazepine
MU Yonggang , NA Wanqiu , CHEN Ke , PAN Xingen , CHEN Xiaoyun , ZHI Shengli , CHEN Zheli . Application of PDCA cycle management on the rational use of benzodiazepines in dementia patients with sleep disorders[J]. Chinese Journal of Alzheimer's Disease and Related Disorders, 2021 , 4(1) : 28 -32 . DOI: 10.3969/j.issn.2096-5516.2021.01.004
图1 痴呆伴睡眠障碍苯二氮䓬类药物规范治疗路径图Fig.1 Clinical pathway for the management of sleep disorders in dementia |
表1 PDCA循环管理前后痴呆伴睡眠障碍苯二氮䓬类药物规范合理性使用情况比较(%)Tab.1 Effects of PDCA cycles on Percentage of the rational use of benz for management of sleep disorders in dementia |
项目 | 执行前 | 第1阶段 | 第2阶段 | 第3阶段 | 第4阶段 | 第5-7阶段 |
---|---|---|---|---|---|---|
病例数 | 56 | 15 | 26 | 22 | 30 | 71 |
是否进行睡眠评估 | ||||||
进行睡眠评估 | 4(7.1) | ②10(66.7) | ②25(96.2) | ②19(86.4) | ②28(93.3) | ②71(100) |
未进行睡眠评估 | 52(92.8) | 5(33.3) | 1(3.8) | 3(13.6) | 2(6.7) | 0 |
苯二氮䓬类药物是否符合路径规范 | ||||||
符合路径规范病例数 | 25(44.6) | 11(73.3) | ②23(88.5) | ②19(86.3) | ②29(96.7) | ②71(100) |
不符合路径规范病例数 | 31(55.4) | 4(26.7) | 3(11.5) | 3(13.7) | 1(3.3) | 0 |
Note: Compared with baseline,①P<0.05,②P<0.01. |
表2 PDCA循环管理前后痴呆伴睡眠障碍苯二氮䓬类药物使用中药物相关不良事件发生率比较(%)Tab.2 Effects of PDCA cycles on incidence of adverse events in management of sleep disorders in dementia |
不良事件(%) | 执行前 | 第1阶段 | 第2阶段 | 第3阶段 | 第4阶段 | 第5-7阶段 |
---|---|---|---|---|---|---|
病例数 | 56 | 15 | 26 | 22 | 30 | 71 |
步态不稳 | 15(26.8) | 2(13.3) | 3(11.5) | ①1(4.5) | ②1(3.3) | ②1(1.4) |
嗜睡 | 10(17.9) | 4(26.7) | 3(11.5) | 1(4.5) | 3(10.0) | ②1(1.4) |
谵妄 | 8(14.3) | 0 | 0 | 1(4.5) | ①0 | ②1(1.4) |
肺炎 | 7(12.5) | 1(6.7) | 0 | 0 | 0 | ①2(2.8) |
Note: Compared with baseline, ①P<0.05,②表示P<0.01. |
[1] |
|
[2] |
|
[3] |
|
[4] |
贾建平. 中国痴呆与认知障碍诊疗指南[M]. 北京: 人民卫生出版社, 2016: 27-36.
|
[5] |
陆林. 沈渔邨精神病学[M]. 第6版. 北京: 人民卫生出版社, 2018.
|
[6] |
|
[7] |
朱荣彦, 郭鹏, 张巍, 等. 阿尔茨海默病与睡眠障碍[J]. 中华老年医学杂志, 2017, 36(1): 1-4.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
章瑜, 谢健. 美金刚对阿尔茨海默病患者精神行为症状和睡眠结构的影响[J]. 浙江医学, 2018, 40(11): 1175-1178.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
王玉平, 汪凯, 潘集阳, 等. 中国成人失眠伴抑郁焦虑诊治专家共识[J]. 中华神经科杂志, 2020, (8): 564-574.
|
[18] |
|
[19] |
|
[20] |
|
/
〈 |
|
〉 |